Reporting from ASCO 2023 Annual Meeting, Philipp Harter discusses the results from the SHAPE trial evaluating both outcome and quality of life at 3 years of simple vs radical hysterectomy in low-risk early stage cervical cancer. He also presents some encouraging PFS results from the interim analysis of the DUO-O trial, testing the addition of durvalumab alone and in combination with olaparib to the PC plus bevacizumab regimen, in advanced Ovarian Cancer without a BRCA1/2 mutation. Further analysis and longer follow-up are needed to confirm these results, and the potential benefit in the HRD negative population.
Abstracts discussed:
- LBA5511: An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
- LBA5506: Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.